$1.68 0.1 3.1%
Last Trade - 22/01/21
| Market Cap | ÂŁ57.6m |
| Enterprise Value | ÂŁ42.8m |
| Revenue | ÂŁn/a |
| Position in Universe | 4977th / 6626 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company. The Company is focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. It is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its pipeline includes reloxaliase and ALLN-346. Reloxaliase is an oral enzyme therapeutic that is being developed for the treatment of hyperoxaluria. ALLN-346 is designed to be an orally-administered non-absorbed urate-degrading enzyme. ALLN-346 is being developed to degrade urate in the gastrointestinal (GI) tract.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | June 24, 2011 |
| Public Since | November 2, 2017 |
| No. of Shareholders: | 20 |
| No. of Employees: | 22 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 48,518,925 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 Newton Executive Park Ste 202, NEWTON, 02462-1435, United States |
| Web | http://www.allenapharma.com/ |
| Phone | +1 617 4674577 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 22/01/21, shares in Allena Pharmaceuticals Inc are trading at $1.68, giving the company a market capitalisation of ÂŁ57.6m. This share price information is delayed by 15 minutes.
Shares in Allena Pharmaceuticals Inc are currently trading at $1.68 and the price has moved by -38.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Allena Pharmaceuticals Inc price has moved by -46.49% over the past year.
Of the analysts with advisory recommendations for Allena Pharmaceuticals Inc, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Allena Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Allena Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
Allena Pharmaceuticals Inc does not currently pay a dividend.
Allena Pharmaceuticals Inc does not currently pay a dividend.
Allena Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in Allena Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Allena Pharmaceuticals Inc are currently trading at $1.68, giving the company a market capitalisation of ÂŁ57.6m.
Here are the trading details for Allena Pharmaceuticals Inc:
Based on an overall assessment of its quality, value and momentum, Allena Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Allena Pharmaceuticals Inc are currently priced at $1.68. At that level they are trading at 0.256% discount to the analyst consensus target price of 0.00.
Analysts covering Allena Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.958 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allena Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -16.92%. At the current price of $1.68, shares in Allena Pharmaceuticals Inc are trading at 8.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Allena Pharmaceuticals Inc.
Allena Pharmaceuticals Inc's management team is headed by:
Here are the top five shareholders of Allena Pharmaceuticals Inc based on the size of their shareholding:
